Structure-based design of an agonistic peptide targeting Fas

Apoptosis

Volumn 10, Issue 2, 2005, Pages 323-329

  Yoshimori, A ^a   Takasawa, R ^a   Hayakawa, A ^b   Mizuno, M ^b   Yoshida, J ^b   Tanuma, S ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Fas; Fas ligand; Peptide mimetics; Structure based drug design

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; FAS ANTIGEN; FAS REACTIVE PEPTIDE 4; PEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; ANTIGENS, CD95; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CELL LINE, TUMOR; DITHIOTHREITOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FEMALE; FLOW CYTOMETRY; HUMANS; MODELS, MOLECULAR; MODELS, STATISTICAL; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDES; POLY(ADP-RIBOSE) POLYMERASES; PROPIDIUM; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TUMOR NECROSIS FACTOR; SOFTWARE;

EID: 18144391896     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10495-005-0806-6     Document Type: Article

References (42)

1. Ellis RE, Yuan JY, Horvitz HR. Mechanisms and functions of cell death. Annu Rev Cell Biol 1991; 7: 663-698.
2. Tanuma S. Molecular mechanics of apoptosis. In: Sluyser M, ed. Apoptosis in Normal Development and Cancer. London, UK: Taylor & Francis 1996: 39-59.
3. Nicholson DW, Thornberry NA. Caspases: Killer proteases. Trends Biochem Sci 1997; 22: 299-306.
4. Utz PJ, Anderson P. Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules. Cell Death Differ 2000; 7: 589-602.
5. Wyllie AH, Kerr JF, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
6. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
7. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305-1308.
8. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000; 256: 58-66.
9. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-1687.
10. Kroemer G., Reed JC. Mitochondrial control of cell death. Nature Med. 2000; 6: 513-519.
11. Cohen GM. Caspases: The executioners of apoptosis. Biochem J 1997; 326: 1-16.
12. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999; 68: 383-424.
13. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43-50.
14. Shiokawa D, Tanuma S. Molecular cloning and expression of a cDNA encoding an apoptotic endonuclease DNase gamma. Biochem J 1998; 332: 713-720.
15. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001; 412: 95-99.
16. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281: 1322-1326.
17. Chao DT, Korsmeyer SJ. BCL-2 family: Regulators of cell death. Annu Rev Immunol 1998; 16: 395-419.
18. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 1989; 169: 1747-1756.
19. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245, 301-305.
20. Sharma K, Wang RX, Zhang LY, et al. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 2000; 88: 333-347.
21. Sakamaki K, Yoshida H, Nishimura Y, Nishikawa S, Manabe N, Yonehara S. Involvement of Fas antigen in ovarian follicular atresia and luteolysis. Mol Reprod Dev 1997, 47, 11-18.
22. Starling GC, Bajorath, J, Emswiler J, Ledbetter JA, Aruffo A, Kiener PA. Identification of ammo acid residues important for ligand binding to Fas. J Exp Med 1997; 185: 1487-1492.
23. Starling GC, Kiener PA, Aruffo A, Bajorath J. Analysis of the ligand binding site in Fas (CD95) by site-directed mutagenesis and comparison with TNFR and CD40. Biochemistry 1998; 37: 3723-3726.
24. Yoshimori A, Takasawa R, Tanuma S. A novel method for evaluation and screening of caspase inhibitory peptides by the amino acid positional fitness score. BMC Pharmacol 2004; 4: 7.
25. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273: 458-464.
26. Livnah O, Stura EA, Johnson DL. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996; 273: 464-471.
27. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997, 276, 1696-1699.
28. Elton TS, Dion LD, Bost KL, Oparil S, Blalock JE. Purification of an angiotensin II binding protein by using antibodies to a peptide encoded by angiotensin II complementary RNA. Proc Natl Acad Sci USA 1988; 85: 2518-2522.
29. Fassina G, Cassani G, Corti A. Binding of human tumor necrosis factor alpha to multimeric complementary peptides. Arch Biochem Biophys 1992; 296: 137-143-
30. Hayakawa A, Kojima T, Yokoyama I, Suzuki H, Tajiri H, Nakashima I. A short peptide derived from the antisense homology box of Fas ligand induces apoptosis in anti-Fas antibody-insensitive human ovarian cancer cells. Apoptosis 2000; 5: 37-41.
31. Hayakawa A, Yokoyama I, Tajiri H, Okamoto T, Nakashima I. Protein kinase C-dependent anti-apoptotic mechanism that is associated with high sensitivity to anti-Fas antibody in ovarian cancer cell lines. Cancer Lett 1999; 140: 113-119.
32. Hayakawa A, Wu J, Kawamoto Y, et al. Activation of caspase-8 is critical for sensitivity to cytotoxic anti-Fas antibody-induced apoptosis in human ovarian cancer cells. Apoptosis 2002; 7: 107-113.
33. Gallet X, Charloteaux B, Thomas A, Brasseur R. A fast method to predict protein interaction sites from sequences. J Mol Biol 2000; 302: 917-926.
34. Eisenberg D, Schwarz E, Komaromy M, Wall R. Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J Mol Biol 1984; 179: 125-142.
35. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19: 1639-1662.
36. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490
37. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
38. Jiang Y, Woronicz JD, Liu W, Goeddel DV. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999; 283: 543-546.
39. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14: 5579-5588.
40. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997; 25: 4876-4882.
41. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779-815.
42. Marti-Renom MA, Stuart A, Fiser A, Sánchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000; 29: 291-325.